Huaheng Biotechnology (688639) 2025 Annual Report Brief Analysis: Revenue Growth Without Profit Growth, Company Has Large Accounts Receivable

According to publicly available data compiled by Securities Star, Huaheng Biological (688639) recently released its 2025 annual report. As of the end of this reporting period, the company’s total operating revenue was 2.862 billion yuan, an increase of 31.4% year-over-year, and net profit attributable to shareholders was 132 million yuan, a decrease of 30.13% year-over-year. Looking at quarterly data, in the fourth quarter, total operating revenue was 668 million yuan, up 4.6% year-over-year, while net profit attributable to shareholders was -35.2094 million yuan, down 279.41% year-over-year. During this reporting period, Huaheng Biological had a large accounts receivable balance, with accounts receivable accounting for 204.85% of the latest annual report’s net profit attributable to shareholders.

This figure is below most analyst expectations, which previously projected a net profit of around 261 million yuan for 2025.

The financial report shows average performance across various indicators. The gross profit margin was 21.27%, down 14.67% year-over-year; net profit margin was 4.33%, down 48.93% year-over-year; total sales, management, and financial expenses amounted to 330 million yuan, accounting for 11.29% of revenue, up 0.78%; net asset value per share was 10.58 yuan, up 3.04%; operating cash flow per share was 0.42 yuan, down 47.75%; earnings per share were 0.53 yuan, down 35.37%.

The explanations for significant changes in financial items are as follows:

1. Management expenses increased by 31.8%, due to higher employee compensation, software service fees, and depreciation costs.
2. Financial expenses increased by 93.25%, mainly due to reduced exchange gains.
3. Net cash flow from operating activities decreased by 47.67%, due to increased cash payments for raw materials and other expenses.
4. Net cash flow from investing activities increased by 30.82%, as cash payments for fixed assets, intangible assets, and other long-term assets decreased.
5. Net cash flow from financing activities decreased by 47.59%, mainly because the company issued shares to specific investors in the previous period.
6. Cash and cash equivalents decreased by 32.77%, due to investments.
7. Changes in notes receivable increased by 113.24%, due to increased settlement of payments via notes.
8. Prepaid expenses increased by 80.77%, mainly due to higher prepayments for electricity.
9. Inventory increased by 30.77%, to meet operational needs.
10. Other current assets increased by 58.44%, due to higher VAT receivables.
11. Fixed assets increased by 64.95%, as some construction-in-progress projects reached usable status and were transferred to fixed assets.
12. Long-term deferred expenses increased by 135.52%, mainly due to increased renovation costs.
13. Deferred tax assets increased by 67.9%, due to higher deductible losses.
14. Other non-current assets decreased by 52.92%, mainly due to reduced prepayments for engineering equipment.
15. Short-term borrowings decreased by 81.91%, as the company restructured its financing to shift towards long-term loans.
16. Non-current liabilities due within one year increased by 60.81%, due to reclassification of the expected repayment portion of newly issued long-term loans.
17. Long-term borrowings increased by 146.54%, as the company restructured its financing to long-term debt.
18. Deferred tax liabilities increased by 33.56%, due to a one-time increase in depreciation deductions for fixed assets.
19. Operating revenue increased by 31.4%, driven by higher sales of amino acid products.
20. Operating costs increased by 37.8%, reflecting higher production and sales volumes.

Securities Star’s valuation analysis tools indicate:

• Business Evaluation: The company’s ROIC last year was 3.66%, indicating weak capital returns. The net profit margin was 4.33%, suggesting limited added value from products or services after all costs. Historically, since listing, the median ROIC has been 22.11%, with strong investment returns overall. The worst year was 2012, with an ROIC of 3.23%. The company’s financials have been relatively stable, with four annual reports since listing and only one loss year, warranting further investigation for any special reasons.
• Debt Servicing Ability: The company’s interest-bearing debt relative to current profits is significant, and growth in interest-bearing liabilities has driven performance, suggesting potential debt overload risks.
• Business Model: The company’s performance mainly relies on R&D, debt financing, and capital expenditures. Attention should be paid to whether capital expenditures are cost-effective and whether funding pressures are rigid. A detailed review of these drivers is necessary.
• Business Breakdown: Over the past three years (2023/2024/2025), net return on net operating assets was 16.3%, 5%, and 2.8%, respectively. Net operating profits were 447 million, 185 million, and 124 million yuan; net operating assets were 2.744 billion, 3.659 billion, and 4.454 billion yuan.

The company’s working capital to revenue ratio over the past three years was -0.02, 0.09, and 0.08, with working capital (funds invested by the company itself) at -41.9195 million, 192 million, and 242 million yuan, and revenue at 1.938 billion, 2.178 billion, and 2.862 billion yuan.

Financial health check tools suggest:

1. Pay attention to cash flow status (cash and cash equivalents / current liabilities only 45.34%).
2. Monitor debt levels (interest-bearing liabilities ratio has reached 35.65%, and total interest-bearing debt / average operating cash flow over the past three years is 10.2%).
3. Watch accounts receivable status (accounts receivable / profit has reached 204.85%).

The fund holding the largest position in Huaheng Biological is China Merchants Bank’s Advanced Manufacturing Hybrid A, with a scale of 4.223 billion yuan, latest net value of 6.0637 (as of March 18), up 1.14% from the previous trading day, and up 48.33% over the past year. The current fund manager is Guo Ruo.

The above information is compiled from publicly available data by Securities Star, generated by AI algorithms (Network Credit Record 310104345710301240019), and does not constitute investment advice.